Aberrant expression of wild-type WT1 was detected in various malignancies, especially breast cancer [12, 13], ovarian cancer [14], hepatocellular carcinoma [15, 16], leukemia [17–19], and neuroepithelial tumor [20]. Here, WT1 is linked to leukemia.